Art. 21 Directive (EU) 2001/83

In forcesince 20 Jan 2011cited 14×
1.

When the marketing authorization is issued, the holder shall be informed, by the competent authorities of the Member State concerned, of the summary of the product characteristics as approved by it.

2.

The competent authorities shall take all necessary measures to ensure that the information given in the summary is in conformity with that accepted when the marketing authorization is issued or subsequently.

3.

The national competent authorities shall, without delay, make publicly available the marketing authorisation together with the package leaflet, the summary of the product characteristics and any conditions established in accordance with Articles 21a, 22 and 22a, together with any deadlines for the fulfilment of those conditions for each medicinal product which they have authorised.

4.

The national competent authorities shall draw up an assessment report and make comments on the file as regards the results of the pharmaceutical and pre-clinical tests, the clinical trials, the risk management system and the pharmacovigilance system of the medicinal product concerned. The assessment report shall be updated whenever new information becomes available which is important for the evaluation of the quality, safety or efficacy of the medicinal product concerned.

The national competent authorities shall make the assessment report publicly accessible without delay, together with the reasons for their opinion, after deletion of any information of a commercially confidential nature. The justification shall be provided separately for each indication applied for.

The public assessment report shall include a summary written in a manner that is understandable to the public. The summary shall contain, in particular, a section relating to the conditions of use of the medicinal product.

The 10 that are cited most themselves, of 14.

  • Directive (EU) 2004/27Lawamends

  • Opinion of Advocate General Sharpston delivered on 31 January 2013. Novartis Pharma GmbH v Apozyt GmbH.Decision

    According to Article 21(1), when a marketing authorisation is issued, the competent authorities of the Member State to whom the application was made are to inform the holder of the summary of the product characteristics as approved by them.

    31 Jan 2013 · 62011CC0535

  • Directive (EU) 2010/84Lawamends

  • Judgment of the General Court (Third Chamber) of 14 December 2011. Nycomed Danmark ApS v European Medicines Agency (EMA).Decision

    It should be noted in that regard that, according to Article 8(3)(e) and Article 11 of Directive 2001/83, which are also applicable to applications for marketing authorisation provided for in Article 6 of Regulation No 726/2004, such …

    14 Dec 2011 · 62009TJ0052

  • Judgment of the General Court (Tenth Chamber) of 23 September 2020 (Extracts). Medac Gesellschaft für klinische Spezialpräparate mbH v EuropDecision

    Next, with a view to the grant of an MA at national level, an application must be made to the competent authority of the Member State concerned. That application must include an SmPC, pursuant to Article 8(3)(j) of Directive 2001/83. …

    23 Sep 2020 · 62019TJ0549

  • Opinion of Advocate General Bobek delivered on 7 December 2017. Proceedings brought by Astellas Pharma GmbH.Decision

    The holder had to make it possible for the reference Member State to verify whether the dossier related to the initial marketing authorisation and the dossier related to the mutual recognition procedure were identical. A request also had …

    7 Dec 2017 · 62016CC0557

  • BVerwG, Urteil vom 23. April 2020 - 3 C 22/18Decision

    … 8 Abs. 3 Buchst. j i.V.m. Art. 11 der Richtlinie 2001/83/EG strikte Vorgaben. Nach Art. 21 Abs. 2 der Richtlinie 2001/83/EG trifft die zuständige Behörde alle zweckdienlichen Maßnahmen, damit die in der Zusammenfassung enthaltenen …

    23 Apr 2020 · WBRE202000426

  • Opinion of Mr Advocate General Jääskinen delivered on 19 October 2010. Novo Nordisk AS v Ravimiamet.Decision

    The summary contains essential therapeutic, pharmacological and pharmaceutical information concerning the medicinal products. [Article 11 of Directive 2001/83.] That information is monitored and verified by the competent authority [Article …

    19 Oct 2010 · 62009CC0249

  • Judgment of the Court (Sixth Chamber) of 14 February 2019. Staat der Nederlanden v Warner-Lambert Company LLC.Decision

    This request for a preliminary ruling concerns the interpretation of Article 11 and Article 21(3) of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products …

    14 Feb 2019 · 62017CJ0423

  • Opinion of Advocate General Kokott delivered on 4 October 2018. Staat der Nederlanden v Warner-Lambert Company LLC.Decision

    In connection with the authorisation procedure, Article 21(2) and (3) of Directive 2001/83 imposes the following duties on the authorities: ‘2. The competent authorities shall take all necessary measures to ensure that the information …

    4 Oct 2018 · 62017CC0423